 | • レポートコード：MRC23Q36130 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のコウニス症候群治療市場について調査・分析し、世界のコウニス症候群治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（β-ラクタム系抗生物質、非ステロイド性抗炎症薬、ロクロニウム、その他）、用途別セグメント分析（研究所、病院＆診療所）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Roche、Amgen、B-MS、Merck、Pfizer、Novartis、Eli Lilly and Company、Johnson & Johnson、GSK、Sanofi、Boehringer Ingelheim、Zhejiang Jiuzhou Pharmaceuticalなどが含まれています。 世界のコウニス症候群治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、コウニス症候群治療市場規模を推定する際に考慮しました。本レポートは、コウニス症候群治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、コウニス症候群治療に関するビジネス上の意思決定に役立てることを目的としています。 ・コウニス症候群治療市場の概要 - コウニス症候群治療のタイプ別セグメント - 世界のコウニス症候群治療市場規模：タイプ別分析（β-ラクタム系抗生物質、非ステロイド性抗炎症薬、ロクロニウム、その他） - コウニス症候群治療の用途別セグメント - 世界のコウニス症候群治療市場規模：用途別分析（研究所、病院＆診療所） - 世界のコウニス症候群治療市場規模予測（2018年-2029年） ・コウニス症候群治療市場の成長トレンド - コウニス症候群治療の地域別市場規模（2018年-2029年） - コウニス症候群治療市場ダイナミクス - コウニス症候群治療の業界動向 - コウニス症候群治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：β-ラクタム系抗生物質、非ステロイド性抗炎症薬、ロクロニウム、その他 - 世界のコウニス症候群治療のタイプ別市場規模（2018年-2023年） - 世界のコウニス症候群治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：研究所、病院＆診療所 - 世界のコウニス症候群治療の用途別市場規模（2018年-2023年） - 世界のコウニス症候群治療の用途別市場規模（2024年-2029年） ・コウニス症候群治療の地域別市場規模 - 北米のコウニス症候群治療市場規模（2018年-2029年） - アメリカのコウニス症候群治療市場規模（2018年-2029年） - ヨーロッパのコウニス症候群治療市場規模（2018年-2029年） - アジア太平洋のコウニス症候群治療市場規模（2018年-2029年） - 中国のコウニス症候群治療市場規模（2018年-2029年） - 日本のコウニス症候群治療市場規模（2018年-2029年） - 韓国のコウニス症候群治療市場規模（2018年-2029年） - インドのコウニス症候群治療市場規模（2018年-2029年） - オーストラリアのコウニス症候群治療市場規模（2018年-2029年） - 中南米のコウニス症候群治療市場規模（2018年-2029年） - 中東・アフリカのコウニス症候群治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Roche、Amgen、B-MS、Merck、Pfizer、Novartis、Eli Lilly and Company、Johnson & Johnson、GSK、Sanofi、Boehringer Ingelheim、Zhejiang Jiuzhou Pharmaceutical ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Kounis Syndrome Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Kounis Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Kounis Syndrome Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Kounis Syndrome Treatment in Laboratories is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Kounis Syndrome Treatment include Roche, Amgen, B-MS, Merck, Pfizer, Novartis, Eli Lilly and Company, Johnson & Johnson and GSK, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Kounis Syndrome Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kounis Syndrome Treatment.
The Kounis Syndrome Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Kounis Syndrome Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kounis Syndrome Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Roche
Amgen
B-MS
Merck
Pfizer
Novartis
Eli Lilly and Company
Johnson & Johnson
GSK
Sanofi
Boehringer Ingelheim
Zhejiang Jiuzhou Pharmaceutical
Segment by Type
Beta-lactam Antibiotics
Non-steroidal Anti-inflammatory Drugs
Rocuronium
Others
Segment by Application
Laboratories
Hospitals & Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kounis Syndrome Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kounis Syndrome Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Beta-lactam Antibiotics
1.2.3 Non-steroidal Anti-inflammatory Drugs
1.2.4 Rocuronium
1.2.5 Others
1.3 Market by Application
1.3.1 Global Kounis Syndrome Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Laboratories
1.3.3 Hospitals & Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kounis Syndrome Treatment Market Perspective (2018-2029)
2.2 Kounis Syndrome Treatment Growth Trends by Region
2.2.1 Global Kounis Syndrome Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Kounis Syndrome Treatment Historic Market Size by Region (2018-2023)
2.2.3 Kounis Syndrome Treatment Forecasted Market Size by Region (2024-2029)
2.3 Kounis Syndrome Treatment Market Dynamics
2.3.1 Kounis Syndrome Treatment Industry Trends
2.3.2 Kounis Syndrome Treatment Market Drivers
2.3.3 Kounis Syndrome Treatment Market Challenges
2.3.4 Kounis Syndrome Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kounis Syndrome Treatment Players by Revenue
3.1.1 Global Top Kounis Syndrome Treatment Players by Revenue (2018-2023)
3.1.2 Global Kounis Syndrome Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Kounis Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kounis Syndrome Treatment Revenue
3.4 Global Kounis Syndrome Treatment Market Concentration Ratio
3.4.1 Global Kounis Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kounis Syndrome Treatment Revenue in 2022
3.5 Kounis Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players Kounis Syndrome Treatment Product Solution and Service
3.7 Date of Enter into Kounis Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kounis Syndrome Treatment Breakdown Data by Type
4.1 Global Kounis Syndrome Treatment Historic Market Size by Type (2018-2023)
4.2 Global Kounis Syndrome Treatment Forecasted Market Size by Type (2024-2029)
5 Kounis Syndrome Treatment Breakdown Data by Application
5.1 Global Kounis Syndrome Treatment Historic Market Size by Application (2018-2023)
5.2 Global Kounis Syndrome Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Kounis Syndrome Treatment Market Size (2018-2029)
6.2 North America Kounis Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Kounis Syndrome Treatment Market Size by Country (2018-2023)
6.4 North America Kounis Syndrome Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kounis Syndrome Treatment Market Size (2018-2029)
7.2 Europe Kounis Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Kounis Syndrome Treatment Market Size by Country (2018-2023)
7.4 Europe Kounis Syndrome Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kounis Syndrome Treatment Market Size (2018-2029)
8.2 Asia-Pacific Kounis Syndrome Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Kounis Syndrome Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Kounis Syndrome Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kounis Syndrome Treatment Market Size (2018-2029)
9.2 Latin America Kounis Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Kounis Syndrome Treatment Market Size by Country (2018-2023)
9.4 Latin America Kounis Syndrome Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kounis Syndrome Treatment Market Size (2018-2029)
10.2 Middle East & Africa Kounis Syndrome Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Kounis Syndrome Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Kounis Syndrome Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Kounis Syndrome Treatment Introduction
11.1.4 Roche Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Kounis Syndrome Treatment Introduction
11.2.4 Amgen Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.2.5 Amgen Recent Development
11.3 B-MS
11.3.1 B-MS Company Detail
11.3.2 B-MS Business Overview
11.3.3 B-MS Kounis Syndrome Treatment Introduction
11.3.4 B-MS Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.3.5 B-MS Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Kounis Syndrome Treatment Introduction
11.4.4 Merck Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Kounis Syndrome Treatment Introduction
11.5.4 Pfizer Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.5.5 Pfizer Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Kounis Syndrome Treatment Introduction
11.6.4 Novartis Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Detail
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Kounis Syndrome Treatment Introduction
11.7.4 Eli Lilly and Company Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.7.5 Eli Lilly and Company Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Kounis Syndrome Treatment Introduction
11.8.4 Johnson & Johnson Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 GSK
11.9.1 GSK Company Detail
11.9.2 GSK Business Overview
11.9.3 GSK Kounis Syndrome Treatment Introduction
11.9.4 GSK Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.9.5 GSK Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Kounis Syndrome Treatment Introduction
11.10.4 Sanofi Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.10.5 Sanofi Recent Development
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Detail
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Kounis Syndrome Treatment Introduction
11.11.4 Boehringer Ingelheim Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.11.5 Boehringer Ingelheim Recent Development
11.12 Zhejiang Jiuzhou Pharmaceutical
11.12.1 Zhejiang Jiuzhou Pharmaceutical Company Detail
11.12.2 Zhejiang Jiuzhou Pharmaceutical Business Overview
11.12.3 Zhejiang Jiuzhou Pharmaceutical Kounis Syndrome Treatment Introduction
11.12.4 Zhejiang Jiuzhou Pharmaceutical Revenue in Kounis Syndrome Treatment Business (2018-2023)
11.12.5 Zhejiang Jiuzhou Pharmaceutical Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details